Pinki Chowdhury

Pinki Chowdhury

Auto-generated profile, based on publicly available information

Pinki Chowdhury

Department of Pediatrics, Dayton Children’s Hospital, Wright State University Boonshoft School of Medicine, Dayton, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2022 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
XGXiangrong Geng
Xiangrong Geng
CWChenguang Wang
Chenguang Wang
XGXin Gao
Xin Gao
PCPinki Chowdhury
Pinki Chowdhury
JWJonathan Weiss
Jonathan Weiss
RWRyan Wilcox
Ryan Wilcox
Neoplasms originating from thymic T-cell progenitors and post-thymic mature T-cell subsets account for a minority of lymphoproliferative neoplasms. These T-cell derived neoplasms, while molecularly and genetically heterogeneous, exploit transcription factors and signaling pathways that are critically important in normal T-cell biology, including those implicated in antigen-, costimulatory-, and cytokine-receptor signaling. The transcription factor GATA-3 regulates the growth and proliferation of both immature and mature T cells and has recently been implicated in T-cell neoplasms, including the most common mature T-cell lymphoma observed in much of the Western world. Here we show that GATA-3 is a proto-oncogene across the spectrum of T-cell neoplasms, including those derived from T-cell progenitors and their mature progeny, and further define the transcriptional programs that are GATA-3 dependent, which include therapeutically targetable gene products. The discovery that p300-dependent acetylation regulates GATA-3 mediated transcription by attenuating DNA binding has novel therapeutic implications. As most patients afflicted with GATA-3 driven T-cell neoplasms will succumb to their disease within a few years of diagnosis, these findings suggest opportunities to improve outcomes for these patients.